Li YS, et al. - Via retrospectively gathered clinical data from 120 consecutive patients who were diagnosed with gastrointestinal stromal tumors (GISTs), researchers assessed the efficacy different imatinib treatment regimens and how patients’ survival could be impacted. Patients underwent tumor resection for high-risk GISTs and either received postoperative imatinib adjuvant therapy regularly (regular treatment group), were not treated with imatinib until they had disease progression (observation group), or were treated with postoperative imatinib adjuvant therapy irregularly (irregularly treatment group). Independent prognostic factors influencing overall survival (OS) were the extent of radical resection and intraoperative tumor rupture. Worse progression-free survival was correlated to irregular administration of imatinib, but no impact on OS in patients with high-risk GISTs was noted. Furthermore, an association of avoiding intraoperative tumor rupture and R0 resection with better survival was also noted.